The EGALITY study: a confirmatory, randomized, double-blind stydy comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis

Griffiths CEM, Thaci D, Gerdes S, Arenberger P, Pulka G, Kingo K, Weglowska J, EGALITY study group, Hattebuhr N, Poetzl J, Woehling H, Wuerth G, Afonso M. (2017). The EGALITY study: a confirmatory, randomized, double-blind stydy comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. British Journal of Dermatology, 176 (4), 928−938.10.1111/bjd.15152.
ajakirjaartikkel
Griffiths CEM, Thaci D, Gerdes S, Arenberger P, Pulka G, Kingo K, Weglowska J, EGALITY study group, Hattebuhr N, Poetzl J, Woehling H, Wuerth G, Afonso M.
  • Inglise
British Journal of Dermatology
1365-2133
176
4
2017
928938
Ilmunud
1.1. Teadusartiklid, mis on kajastatud Web of Science andmebaasides Science Citation Index Expanded, Social Sciences Citation Index, Arts & Humanities Citation Index ja/või andmebaasis Scopus (v.a. kogumikud)
WOS

Viited terviktekstile

dx.doi.org/10.1111/bjd.15152

Lisainfo

Article